Can neuronal-surface antibodies disrupt synaptic receptor or ion-channel function and contribute to cognitive and neuropsychiatric dysfunction?

Neuronal-surface antibody syndromes are important, potentially treatable causes of subacute cognitive, behavioral, and neuropsychiatric illness. The overall claim is strongly supported for direct synaptic receptor/ion-channel dysfunction and its clinical consequences; the role of neuroinflammation is credible but variable across antibody targets and syndromes.

Direct synaptic and channel effects

• Patient-derived glycine-receptor antibodies nearly abolished glycinergic miniature synaptic currents in cultured motor neurons within 15 minutes. Persistence of this effect with monovalent Fab fragments supports direct receptor antagonism rather than requiring receptor cross-linking or internalization.
• CSF-derived GABA(_A)-receptor monoclonal antibodies similarly reduced inhibitory currents without detectable receptor internalization; in mice, these antibodies caused seizures, catatonia/encephalopathy, and increased mortality.
• CASPR2 IgG reduces Kv1-channel conductance, increases neuronal excitability, disrupts Kv1-associated organization, and alters synaptic/network activity. In mice, patient-derived CASPR2 IgG produced reversible memory impairment.

Mechanisms

• Mechanisms are target- and epitope-specific. NMDAR IgG1 can cross-link and internalize NMDARs, reducing synaptic receptor function. CASPR2 IgG can also induce CASPR2 internalization, accompanied by reduced Kv1.1 and GluA1.
• Direct antagonism can occur independently of internalization, particularly for GlyR and GABA(_A) receptor antibodies. These mechanisms converge on loss of inhibition, altered excitation–inhibition balance, and abnormal network activity.

Neuroinflammation and clinical manifestations

• Inflammatory CSF profiles are common in NMDAR, GABA-B receptor, and AMPAR encephalitides, but often absent in LGI1 and CASPR2 disease. A CASPR2 case showed complement deposition, perivascular B/plasma cells, and microglial activation, supporting inflammation in selected contexts.
• Cognitive decline, memory loss, psychiatric/behavioral symptoms, and fluctuating cognition are characteristic. In a prospective rapidly progressive dementia cohort, 88% of followed autoimmune-encephalitis patients improved after immunotherapy.

Bottom line

• Pathogenic neuronal-surface antibodies can directly impair receptor and channel function and thereby produce cognitive and neuropsychiatric dysfunction. Neuroinflammation likely contributes in some syndromes, but is not a uniform or independently established driver across all antibody-mediated diseases.